News

Appointment strengthens GA’s commercial leadership as GA-map® adoption expands across the USA, Europe, Asia and Australia Oslo, Norway – 3…

OSLO, NORWAY – August 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the half-year report for H1,…

Oslo, Norway / Sydney, Australia – 21.08.2026: Genetic Analysis AS (GA), a leader in microbiome diagnostics and developer of the…

OSLO, NORWAY – 16 July 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the publication of a peer-reviewed study…

OSLO, NORWAY – May 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the…

OSLO, NORWAY – 20 May 2026: The Annual General Meeting in Genetic Analysis AS (the “Company”) was held on Wednesday…

OSLO, NORWAY – 7 May 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the United States Patent And…

OSLO, NORWAY – 5 May 2026: Notice is hereby served that the annual general meeting in Genetic Analysis AS (the…

OSLO, NORWAY – 4 May 2026: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the…

OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress…

OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test…

OSLO, NORWAY – February 27, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the year-end report for 2025….

OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has…

OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important…

OSLO, NORWAY – November 27, 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for Q3,…